J. Mel Sorensen
2021
In 2021, J. Mel Sorensen earned a total compensation of $2.5M as President and Chief Executive Officer at Galera Therapeutics, a 14% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $240,733 |
|---|---|
| Option Awards | $1,713,905 |
| Salary | $568,438 |
| Other | $11,600 |
| Total | $2,534,676 |
Sorensen received $1.7M in option awards, accounting for 68% of the total pay in 2021.
Sorensen also received $240.7K in non-equity incentive plan, $568.4K in salary and $11.6K in other compensation.
Rankings
In 2021, J. Mel Sorensen's compensation ranked 5,092nd out of 12,415 executives tracked by ExecPay. In other words, Sorensen earned more than 59.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,092 out of 12,415 | 59th |
Division Manufacturing | 2,143 out of 5,505 | 61st |
Major group Chemicals And Allied Products | 920 out of 2,375 | 61st |
Industry group Drugs | 823 out of 2,096 | 61st |
Industry Pharmaceutical Preparations | 588 out of 1,546 | 62nd |
Source: SEC filing on April 28, 2022.
Sorensen's colleagues
We found two more compensation records of executives who worked with J. Mel Sorensen at Galera Therapeutics in 2021.
News
Galera Therapeutics CEO J Sorensen's 2023 pay slips 8% to $1.3M
January 24, 2025
Galera Therapeutics CEO J Sorensen's 2022 pay falls 46% to $1.4M
April 27, 2023
Galera Therapeutics CEO J Sorensen's 2021 pay slips 14% to $2.5M
April 28, 2022
Galera Therapeutics CEO J Sorensen's 2019 pay jumps 373% to $2.5M
April 27, 2020